Beaufort Quality Oversight Is Retained By Three Life Science Companies
Beaufort assesses CRO and site performance at clinical sites around the world
NORFOLK, Va., June 20, 2013—Beaufort has been retained by three life science companies to conduct quality oversight programs. Beaufort Quality Oversight provides an independent, continuous and comprehensive assessment of the CRO’s overall process and performance.
Beaufort has been retained by a top pharmaceutical company to perform quality oversight services for two clinical trials. Beaufort senior clinical research professionals located in Europe, Asia-Pacific, North America, and South America will perform assessments of CRO and site performance at clinical sites in 38 countries.
Beaufort also has been retained by a leading provider of innovative pain management therapies to perform quality oversight services for a clinical trial of a controlled substance at 20 sites throughout the U.S. Beaufort’s quality oversight services will include ongoing recommendations for improvement.
Beaufort continues to provide quality oversight services for a top 20 worldwide pharmaceutical company. The company’s director of clinical operations said of the program, “Beaufort’s innovative quality oversight program allows us to ensure the integrity of our clinical research data and exceed FDA requirements.”
Beaufort Quality Oversight is well-aligned with regulatory authority expectations for greater oversight of CROs and other clinical service providers. Independent quality oversight also provides an opportunity for early process improvement, allowing these organizations to identify process enhancements which could improve trial conduct.
“Our partnerships represent a unique value proposition for which Beaufort is an innovator and thought leader,” said John Wilson, Beaufort senior vice president and practice leader. “It provides these organizations an avenue to answer with confidence the question frequently asked during inspections: How do you know your CRO is performing according to expectations?”
Beaufort Quality Oversight is an independent CRO assessment service that provides unbiased, independent assurance that the CRO is performing according to requirements. Beaufort’s niche in the market allows the firm to establish collegial and collaborative relationships with the CROs that manage global clinical trials.
Beaufort representatives will be available to discuss quality oversight and other Beaufort services during the 49th annual meeting of the Drug Information Association, June 23–27 in Boston. Beaufort will exhibit in booth #1916 in the Exhibition Hall.